Trevena Reports Financial Results and Board ChangesOn November 5, 2024, Trevena, Inc. (NASDAQ: TRVN) issued a Form 8-K filing disclosing recent corporate developments. The pharmaceutical company announced several significant changes, including the re

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Trevena’s 8K filing here.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.